NEW YORK (GenomeWeb News) – Gentronix today said that it will provide GlaxoSmithKline with its genotoxicity detection assay, GreenScreen HC, for use in the drug firm's safety evaluation studies.
According to Manchester, UK-based Gentronix, GreenScreen HC is the first human cell-based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay uses green fluorescent protein to detect GADD-45a up regulation, which is a key indicator of DNA damage, said Gentronix.